Post by Bristol Myers Squibb

Today we shared our Q1 earnings results, which reflect continued momentum and execution across the business. Our Growth Portfolio delivered another strong quarter driven by contributions from a broad range of differentiated medicines that are early in their lifecycles. We also made meaningful progress across our pipeline, where we achieved important clinical and regulatory milestones. With the cadence of pivotal readouts expected to increase as the year progresses, we are focused on delivering in the near-term while positioning the company for long-term, sustainable growth. Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/4cR1FUt

Video Content